The pharmaceutical industry is undergoing a transformation, driven by the increasing integration of artificial intelligence (AI) in drug development. This revolution is illustrated by strategic collaborations, significant technological advances, and massive investments. Sanofi, a major player in the sector, embodies this trend with its partnership with OpenAI to accelerate drug discovery. Additionally, the $1.2 billion agreement between Exscientia and Bristol Myers Squibb (BMS) for AI-driven drug discovery underscores major companies' commitment to investing in AI.
Débloquez l'Analyse Complète
Accédez instantanément à nos insights exclusifs générés par IA, basés sur l'agrégation de centaines de sources sectorielles.
